TY  - JOUR
AU  - Capra, Marcelo
AU  - Martin, Thomas
AU  - Moreau, Philippe
AU  - Baker, Ross
AU  - Pour, Ludek
AU  - Min, Chang-Ki
AU  - Leleu, Xavier
AU  - Mohty, Mohamad
AU  - Reinoso Segura, Marta
AU  - Turgut, Mehmet
AU  - LeBlanc, Richard
AU  - Risse, Marie-Laure
AU  - Malinge, Laure
AU  - Schwab, Sandrine
AU  - Dimopoulos, Meletios
PY  - 2022
DO  - 10.3324/haematol.2021.279229
SN  - 0390-6078
UR  - http://hdl.handle.net/10668/20520
T2  - Haematologica
AB  - Renal impairment (RI) is common in patients with multiple myeloma (MM) and new therapies that can improve renal function are needed. The phase III IKEMA study (clinicaltrials gov. Identifier: NCT03275285) investigated isatuximab (Isa) with carfilzomib...
LA  - en
PB  - Ferrata storti foundation
KW  - Low-dose dexamethasone
KW  - Pooled analysis
KW  - Open-label
KW  - Phase-iii
KW  - Lenalidomide
KW  - Bortezomib
KW  - Dialysis
KW  - Failure
KW  - Complications
KW  - Reversibility
TI  - Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
TY  - research article
VL  - 107
ER  -